期刊文献+

乳腺球蛋白在术前乳腺癌和腋窝淋巴结细针穿刺吸取组织中的表达及临床意义 被引量:3

Expression of mammaglobin in preoperatively aspirated breast cancer and axillary lymph node tissues and clinical significance
原文传递
导出
摘要 目的探讨乳腺球蛋白(mammaglobin,MAM)在术前乳腺癌及腋窝淋巴结细针穿刺吸取组织中的表达及临床意义。方法对91例原发性乳腺癌行术前细针穿刺,将吸取的组织制备涂片,采用免疫组织化学方法(EnVision法)检测MAM表达,观察MAM表达与临床病理指标的关系。同时另收集15例原发性肺癌腋窝淋巴结转移患者,分析乳腺癌腋窝淋巴结转移、乳腺癌增生性淋巴结炎和肺癌腋窝淋巴结转移三者间术前腋窝淋巴结MAM表达的区别。统计分析采用χ2检验。结果在91例原发性乳腺癌患者中MAM的阳性表达率为74.72%(68/91)。MAM的阳性表达与雌激素受体(ER)、孕激素受体(PR)、组织学分级、细胞学分级有关(P<0.05),与患者的年龄、肿瘤大小、淋巴结是否转移及HER-2状态无关(P>0.05)。腋窝淋巴结观察结果显示,MAM在乳腺癌腋窝淋巴结转移患者中呈阳性表达,在乳腺癌增生性腋窝淋巴结炎和肺癌腋窝淋巴结转移患者中均为阴性表达。结论 MAM可表达于原发性和转移性乳腺癌,细针穿刺细胞学检查结合MAM的测定对乳腺癌的诊断及鉴别具有一定辅助判断价值。MAM阳性表达与ER、PR状态、细胞学分级、组织学分级有关,有利于了解肿瘤的生物学指标及判断预后。 Objective To investigate the expression of mammaglobin ( MAM ) in preoperative breast carcinoma and axillary lymph node tissues using fine-needle aspiration (FNA) biopsy and its clinical significance. Methods Ninety-one cases of primary breast carcinoma were enrolled into the study. All cases received preoperative fine-needle aspiration biopsy. Immunocytochemistry for testing MAM was performed in all the cases using EnVision method to observe the relation between MAM positive expression and cytologic grading and clinicopathological parameters. In the meantime, 15 primary lung cancer patients were collected, with an intention of comparing the MAM expression in metastatic axillary lymph node of breast cancer, hyperp[astic axillary lymphadenitis of breast cancer and metastatic axillary lymph node of primary lung cancer. Statistical analysis was performed using chi-square test. Results The positive rate of MAM in primary breast carcinoma patients was 74.72% (68/91). The positive expression of MAM was associated with estrogen receptor(ER), progesterone receptor (PR), cytological grade and histologic grade (P〈0.05), while the MAM expression level was independent of age, tumor size, the status of axillary lymph node metastasis and HER-2 (P〉0.05). The observation of MAM expression in axillary lymph nodes showed MAM positively expressed in the metastatic axillary lymph node of breast cancer, but negatively expressed in the hyperplastic axillary lymphadenitis of breast cancer and the metastatic axillary lymph node of primary lung cancer. Conclusion MAM expresses in both primary and metastatic breast carcinomas. FNA combined with testing MAM may be helpful for diagnosis and identification of breast cancer. The correlation of MAM positive expression with the status of ER, PR, cytological grade and histologic grade may have a potential value for preoperatively assessing the biological characteristics and the prognosis of the patients.
出处 《中华乳腺病杂志(电子版)》 CAS 2011年第6期10-14,共5页 Chinese Journal of Breast Disease(Electronic Edition)
基金 徐州市科技计划项目(XM08C089)
关键词 乳腺肿瘤 腋窝淋巴结 乳腺球蛋白 细针穿刺细胞学检查 转移 免疫组织化学法 breast neoplasms axillary lymph node mammaglobin fine-needle aspiration metastasis immunocytochemistry
  • 相关文献

参考文献18

  • 1Watson MA, Dintzis S, Darrow CM, et al. Mammaglobin expression in primary, metastatic, and occult breast cancer [J]. Cancer Res, 1999, 59 (13): 3028-3031. 被引量:1
  • 2Tanaka K, Shoji T, Tominaga Y, et al. Statistical analysis of diagnostic failure of fine needle aspiration cytology ( FNAC ) in breast cancer [J]. J Surg Oncol, 2001,76(2) :100-105. 被引量:1
  • 3Rita N, Cecilia B, Pellegrino C, et al. Immunocytochemical evaluation of HER-2/neu 'on fine-needle aspirates from primary breast eareinomas [J]. Diagn Cytopathol, 2003, 28(3) :142-146. 被引量:1
  • 4Robinsin IA, McKee G, Nieholson A, et al. Prognostic value of cytological grading of fine-needle aspirates from breast carcinomas [ J ]. Lancet, 1994, 343 (8903) :947-949. 被引量:1
  • 5Taniguchi E, Yang Q, Tang W, et al. Cytologic grading of invasive breast carcinoma: correlation with clinicopathologic variables and predictive value of nodal metastasis [ J ]. Acta Cytol, 2000, 44(4) :587 - 591. 被引量:1
  • 6<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:165
  • 7Watson MA, Fleming TP. Mammaglobin, a mammary specific member of the uteroglobin gene family is overexpressed in human breast cancer [J]. Cancer Res, 1996, 56 (4) :860-865. 被引量:1
  • 8O'Brien N,Maguire TM, O'Donovan N, et al. Mammaglobin A: a promising marker for breast cancer [ J ]. Clin Chem, 2002, 48 (8) :1362-1364. 被引量:1
  • 9Fritzsche FR, ThomasA, Winzer KJ, et al. Co-expression andprognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer [ J ]. Histol Histopathol, 2007, 22( 11 ) : 1221-1230. 被引量:1
  • 10Ariga R, Bloom K, Reddy VB, et al. Fine-needle aspiration of clinically suspicious palpable breast masses with histopathologic correlation [J]. Am J Surg, 2002, 184(5) :410 -413. 被引量:1

二级参考文献10

  • 1Watters AD,Going JJ,Cooke GT,et al.Chromosome 17 aneusomy is associated with poor prognostic factors in invesive breast carcinoma.Breast Cancer Res Treat,2003,77:109-114. 被引量:1
  • 2Bilous M,Morey A,Armes J,et al.Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.Pathology,2006,38:120-124. 被引量:1
  • 3Goldhirsch A,Glick JH,Gelber RD,et al.Meeting highlights:international expert consensus on the primary therapy of early breast cancer 2005.Annals Oncol,2005,16:1569-1583. 被引量:1
  • 4The Center For Devices and Radiological Health (CDRH) of the Food and Drug Administration.A document of evaluation about the PathVysionTM HER-2 DNA Probe Kit of Vysis,INC.for detecting amplification of the HER-2/neu gene via fluorescence in situ hybridization (FISH) in formalin-fixed,paraffin-embedded human breast cancer tissue specimens.[2001-12-31].http://www.fda.gov/cdrh/pmapage.html. 被引量:1
  • 5Shak S.Overview of the trastuzumab (Hereeptin) anti-HER2monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer.Herceptin Multinational Investigator Study Group.Semin Oncol,1999,26(4 Suppl 12):71-77. 被引量:1
  • 6Hammock L,Lewis M,Philips,C,et al.Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.Hum Pathol,2003,34:1043-1047. 被引量:1
  • 7北京市发展和改革委员会.关于公布荧光原位杂交基因检测(FISH)等新增医疗服务价格项目的通知.京发改[2006]1376号.http://www.bjpc.gov.cn/tztg/200608/t129145.btm. 被引量:1
  • 8Hicks DG,Tubbs RR.Assessment of the Her2 status in breast cancer by fluorescence in situ hybridization:a technical review with interpretive guidelines.Hum Pathol,2005,36:250-261. 被引量:1
  • 9Wang S,Hossein Saboorian H,Frenkel EP,et al.Aneusomy 17 in breast cancer:its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.Mod Pathol,2002,15:137-145. 被引量:1
  • 10Risio M,Casorzo L,Redana S,et al.HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment.Oncol Rep,2005,13:305-309. 被引量:1

共引文献164

同被引文献15

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部